Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Radioiodine Therapy in Metastatic Thyroid Cancer
NCT05299437Phase 2Unknown
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-131 in differentiated thyroid cancer (DTC). Primary endpoint: Complete Response (CR) rate on soft tissue metastases at 6 months. Status: unknown.
02
Drugs
iodine-131
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05299437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299437.